Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus SERVISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus SERVISONE.
FLUDROCORTISONE ACETATE vs SERVISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
SERVISONE is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to glucocorticoid receptors, modulating gene transcription, and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
0.1 mg orally once daily, range 0.05-0.2 mg/day
10-20 mg orally once daily in the morning; higher doses up to 40 mg daily for severe cases.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal elimination half-life is 3-4 hours. Clinically, this supports twice-daily dosing for sustained effect.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Renal (70-80% as metabolites, 5-10% unchanged); fecal/biliary (15-20%)
Category D/X
Category C
Corticosteroid
Corticosteroid